ALNYLAM PHARMACEUTICALS, INC. Operating Lease, Liability, Noncurrent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Operating Lease, Liability, Noncurrent of $210.50 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-07-30
- 2026-06-30: Operating Lease, Liability, Noncurrent $210.50M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $225.09M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $223.42M.
- 2025-06-30: Operating Lease, Liability, Noncurrent $224.44M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $210.50M 10-Q · filed 2026-07-30 |
| 2025-12-31 | $225.09M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $223.42M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $224.44M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $230.06M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $229.54M 10-K · filed 2026-02-12 |
| 2024-09-30 | $236.03M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $239.35M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $237.83M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $243.10M 10-K · filed 2025-02-13 |
| 2023-09-30 | $247.71M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $253.42M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $259.40M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $261.34M 10-K · filed 2024-02-15 |
| 2022-09-30 | $266.32M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $272.02M 10-Q · filed 2022-07-28 |
| 2022-03-31 | $277.39M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $281.35M 10-K · filed 2023-02-23 |
| 2021-09-30 | $286.03M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $288.56M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $288.01M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $293.04M 10-K · filed 2022-02-10 |
| 2020-09-30 | $297.26M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $281.62M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $275.78M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $276.13M 10-K · filed 2021-02-11 |
| 2019-09-30 | $276.46M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $277.21M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $282.30M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |